Form 4: GRAIL Director Steven Mizell Acquires Equity Compensation

GRAIL, Inc. Director Steven Mizell received 267 deferred stock units valued at $20,164.38 as compensation for his service.

Summary

• Steven Mizell, a Director of GRAIL, Inc., acquired 267 deferred stock units (DSUs).
• These DSUs were granted in lieu of $20,164.38 in cash fees for his service as a director.
• The grant was made under GRAIL's deferred stock program and 2024 Equity Incentive Plan.
• The DSUs were valued at $75.52 per share, which was the closing price of GRAIL's common stock on October 15, 2025.
• The awards vested immediately upon the grant date.
• Following this transaction, Mr. Mizell beneficially owns 36,469 shares of common stock directly.

Sentiment

Score: 6

Explanation: The transaction is a routine insider acquisition of equity compensation, which is generally viewed as a neutral to slightly positive event as it aligns director interests with shareholders. It does not indicate any significant change in company prospects.

Positives

• Aligns the director's financial interests directly with those of the company's shareholders through equity compensation.
• Utilizes the company's 2024 Equity Incentive Plan, indicating active use of established compensation frameworks.
• Immediate vesting of the awards provides clear ownership and reduces future administrative complexity.

Negatives

• No immediate cash payment for the director, which might be a negative for the individual but is a standard practice for equity compensation.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Industry Context

The practice of compensating directors with equity, such as deferred stock units, is a common corporate governance strategy across various industries. It aims to align the interests of the board members with those of the shareholders, encouraging long-term value creation. This transaction by a GRAIL director is consistent with typical compensation structures for board members in publicly traded companies, particularly in the biotechnology or healthcare sector where long-term strategic vision is crucial.

Comparison to Industry Standards

• Compensating directors with equity (DSUs) is a widely accepted practice, aligning director incentives with shareholder value, similar to practices at companies like Illumina, Exact Sciences, or Guardant Health in the diagnostics space.
• The immediate vesting of these awards is also common for director compensation, ensuring that the equity is fully earned for the service rendered.
• The value of the compensation ($20,164.38) for a single transaction is within the typical range for a portion of annual director compensation at a company of GRAIL's size and stage.

Corporate Governance

Stakeholder Impact

• Shareholders: Positive impact as director's interests are further aligned with shareholder value through equity ownership.
• Employees: No direct impact mentioned.
• Customers/Suppliers/Creditors: No direct impact mentioned.

Key Dates

Recommendation

This Form 4 filing details a routine equity compensation grant to a director. While it signifies continued alignment of management interests with shareholders, the transaction's size and nature are not material enough to warrant a change in investment recommendation for GRAIL, Inc. Investors should continue to evaluate the company based on its fundamental performance, strategic initiatives, and broader market conditions.

Keywords

GRAIL Inc., GRAL, Steven Mizell, Form 4, Insider Transaction, Director Compensation, Deferred Stock Units, Equity Incentive Plan, Beneficial Ownership